▶ 調査レポート

微生物叢シーケンシングサービス市場の世界市場:技術別(Sequencing by Litigation(SBL)、Sequencing by Synthesis(SBS)、ショットガンシーケンシング、標的遺伝子配列、RNAシーケンシング、その他)、用途別(消化管疾患、感染症、中枢神経系疾患、腫瘍、その他)、エンドユーザー別、地域別分析

• 英文タイトル:Global Microbiome Sequencing Services Market - Segmented by Technology Type, Applications and End Users - Growth, Trends and Forecasts (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。微生物叢シーケンシングサービス市場の世界市場:技術別(Sequencing by Litigation(SBL)、Sequencing by Synthesis(SBS)、ショットガンシーケンシング、標的遺伝子配列、RNAシーケンシング、その他)、用途別(消化管疾患、感染症、中枢神経系疾患、腫瘍、その他)、エンドユーザー別、地域別分析 / Global Microbiome Sequencing Services Market - Segmented by Technology Type, Applications and End Users - Growth, Trends and Forecasts (2018 - 2023) / B-MOR-040397資料のイメージです。• レポートコード:B-MOR-040397
• 出版社/出版日:Mordor Intelligence / 2018年3月
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Single User(1名様用)¥450,500 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥477,000 (USD4,500)▷ お問い合わせ
  Corporate User¥927,500 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、微生物叢シーケンシングサービス市場の世界市場について調べ、微生物叢シーケンシングサービス市場の世界規模、市場動向、市場環境、技術別(Sequencing by Litigation(SBL)、Sequencing by Synthesis(SBS)、ショットガンシーケンシング、標的遺伝子配列、RNAシーケンシング、その他)分析、用途別(消化管疾患、感染症、中枢神経系疾患、腫瘍、その他)分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・微生物叢シーケンシングサービス市場の世界市場インサイト
・微生物叢シーケンシングサービス市場の世界市場環境
・微生物叢シーケンシングサービス市場の世界市場動向
・微生物叢シーケンシングサービス市場の世界市場規模
・微生物叢シーケンシングサービス市場の世界市場規模:技術別(Sequencing by Litigation(SBL)、Sequencing by Synthesis(SBS)、ショットガンシーケンシング、標的遺伝子配列、RNAシーケンシング、その他)
・微生物叢シーケンシングサービス市場の世界市場規模:用途別(消化管疾患、感染症、中枢神経系疾患、腫瘍、その他)
・微生物叢シーケンシングサービス市場の世界市場規模:エンドユーザー別
・微生物叢シーケンシングサービス市場の世界市場:地域別市場規模・分析
・微生物叢シーケンシングサービス市場の北米市場規模・予測
・微生物叢シーケンシングサービス市場のアメリカ市場規模・予測
・微生物叢シーケンシングサービス市場のヨーロッパ市場規模・予測
・微生物叢シーケンシングサービス市場のアジア市場規模・予測
・微生物叢シーケンシングサービス市場の日本市場規模・予測
・微生物叢シーケンシングサービス市場の中国市場規模・予測
・微生物叢シーケンシングサービス市場のインド市場規模・予測
・微生物叢シーケンシングサービス市場の韓国市場規模・予測
・関連企業情報・競争状況

The global microbiome sequencing services market is expected to register a CAGR of 18.0% during the forecast period, 2018 to 2023. North America dominates the market due to a surge in technological advancement in next-generation sequencing (NGS) projects in the region.

Huge Investment in Microbiome Research

The sequencing of metagenome offers a novel method in diagnosing and treating a wide range of chronic diseases, such as oncology, etc. The metagenome differs from person to person significantly, which is key to its diagnostic potential, due to which the government is investing a large number of funds for microbiome sequencing projects. In 2007, the US National Institutes of Health (NIH) funded USD 140 million to the Human Microbiome Project, which examines all the microorganisms in the human body. In 2008, the European Commission financed USD 29 million for Metagenomics of the Human Intestinal Tract project (MetaHIT). The Wall Street Journal in 2016, reported that from 2011 to 2015, venture funding in microbiome firms climbed by 458.5% to USD114.5 million. About USD 616.9 million was raised for microbiome companies in 2016, which is more than all of the venture investment in the microbiome space between 2011 to 2015 period. Also, rising demand for NGS, surge in genomic research, and widening application area of microbiome sequencing, and a decline in the cost of sequencing are the major factors driving the growth of the market.

Lack of Skilled Technicians for NGS Data Analysis

Lack of technicians in the interpretation of sequencing data is the major factor restricting the growth of the microbiome sequencing services market. Microbiome sequencing generates a huge amount of data, which needs to be interpreted using advanced software. The lack of awareness and knowledge of advanced tools of data analysis among physicians and scientists is the major factor restricting the growth of the global microbiome sequencing services market. Further, government regulations and ethical & legal issues related to NGS are the also restraining the growth of the microbiome sequencing services market.

North America to Dominate the Market

The microbiome sequencing services market is segmented by technology type, application, end user, and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America.
North America dominates the microbiome sequencing services market, owing to factors, such as government support through funds for genomics research, consistent developments in sequencing technologies, and ease in availability of commercial solutions for NGS data analysis. Asia-Pacific is also expected to grow tremendously during the forecast period, owing to growing number of research studies on cancer and inherited rare diseases, and rising demand for next-generation sequencing for diagnosis and therapeutic applications.

Key Developments in the Market

• November 2017: MicroBiome Therapeutics, LLC launched first microbiome modulator. The product is described as an all-natural blend of prebiotics, including fermentable fiber and polyphenol antioxidants, in a patent-pending blend intended to help nurture and nourish beneficial microorganisms in the lower gut.
• June 2017: Zymo Research Corp. launched new kits for Microbiome Research at ASM Microbe 2017.

Major Players: CLINICAL MICROBIOMICS A/S, BASECLEAR B.V., METABIOMICS CORP., MICROBIOME INSIGHTS INC., MICROBIOME THERAPEUTICS, LLC., MR DNA, MERIEUX NUTRISCIENCES CORPORATION, UBIOME, INC., ZYMO RESEARCH CORP., AND SECOND GENOME, among others

Reasons to Purchase this Report

• Current and future global microbiome sequencing services market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Huge Investment in Microbiome Research
6.1.2 Rise in Demand for NGS Services
6.1.3 Decline in Cost of NGS Sequencing
6.1.4 Surge in Genomic Research and Widening Application Area of Microbiome Sequencing
6.2 Market Restraints
6.2.1 Ethical and Legal Issues Related to Genome Sequencing
6.2.2 Lack of Skilled Technicians for NGS Data Analysis
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Technology
7.1.1 Sequencing by Litigation (SBL)
7.1.2 Sequencing by Synthesis (SBS)
7.1.3 Short Gun Sequencing
7.1.4 Targeted Gene Sequencing
7.1.5 RNA Sequencing
7.1.6 Others
7.2 By Application
7.2.1 Gastro-Intestinal Diseases
7.2.2 Infectious Diseases
7.2.3 CNS Diseases
7.2.4 Oncology
7.2.5 Others
7.3 By End User
7.3.1 Research and Academic Institutes
7.3.2 Pharmaceutical and Biotechnology Companies
7.3.3 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest Of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Baseclear B.V.
9.2 Clinical Microbiomics A/S
9.3 Merieux Nutrisciences Corporations
9.4 Metabiomics Corp.
9.5 Microbiome Insights Inc.
9.6 Microbiome Therapeutics, LLC.
9.7 MR DNA
9.8 Second Genome
9.9 Ubiome, Inc.
9.10 Zymo Research Corp.
9.11 Others
10. Future of the Market